ID: ALA1771

Max Phase: Approved

First Approval: 1997

Molecular Formula: C16H16ClNO2S

Molecular Weight: 321.83

Molecule Type: Small molecule

Representations

Synonyms (16): Clopidogrel | Clopidogrel 1a-pharma | Clopidogrel acino | Clopidogrel apotex | Clopidogrel benzenesulfonate | Clopidogrel besilate | Clopidogrel besylate | Clopidogrel hexal | Clopidogrel sandoz | Clopidogrel-ratiopharm | Zyllt | NSC-758613 | R 130964 | R-130964 | SR 25990 | SR-25990
Synonyms from Alternative Forms(16):

Trade Names(3): Grepid | Iscover | Plavix

Canonical SMILES:  COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1

Standard InChI:  InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1

Standard InChI Key:  GKTWGGQPFAXNFI-HNNXBMFYSA-N

Molecule Features

Natural Product: Yes

Oral: Yes

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: Yes

Chirality: Yes

Availability: Yes

Prodrug: Yes

Properties

Molecular Weight: 321.83

Molecular Weight (Monoisotopic): 321.0590

AlogP: 3.67

#Rotatable Bonds: 3

Polar Surface Area: 29.54

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.77

CX LogP: 4.03

CX LogD: 4.03

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.81

Np Likeness Score: -1.58

References

1. Vistoli G, Pedretti A, Mazzolari A, Testa B..  (2010)  In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.,  18  (1): [PMID:19932971] [10.1016/j.bmc.2009.10.052]

2. PubChem BioAssay data set, 

3. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

4.  (2008)  Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, 

5. Fontana E, Dansette PM, Poli SM..  (2005)  Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.,  6  (1): [PMID:16248836] [10.2174/138920005774330639]

6. PubChem BioAssay data set, 

7. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

8. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

9. Vijaya Bhaskar Reddy M, Tsai WJ, Qian K, Lee KH, Wu TS..  (2011)  Structure-activity relationships of chalcone analogs as potential inhibitors of ADP- and collagen-induced platelet aggregation.,  19  (24): [PMID:22055718] [10.1016/j.bmc.2011.08.004]

10. Sun H..  (2012)  Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.,  22  (2): [PMID:22197392] [10.1016/j.bmcl.2011.12.005]

11. Shan J, Zhang B, Zhu Y, Jiao B, Zheng W, Qi X, Gong Y, Yuan F, Lv F, Sun H..  (2012)  Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.,  55  (7): [PMID:22428882] [10.1021/jm300038c]

12. Zhu Y, Zhou J..  (2012)  Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.,  3  (10): [PMID:24900388] [10.1021/ml3002067]

13. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS..  (2012)  Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.,  55  (11): [PMID:22409598] [10.1021/jm300065h]

14. Bach P, Antonsson T, Bylund R, Björkman JA, Österlund K, Giordanetto F, van Giezen JJ, Andersen SM, Zachrisson H, Zetterberg F..  (2013)  Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,  56  (17): [PMID:23899349] [10.1021/jm400820m]

15. Tsai WJ, Shen CC, Tsai TH, Lin LC..  (2014)  Lignans from the aerial parts of Saururus chinensis: isolation, structural characterization, and their effects on platelet aggregation.,  77  (1): [PMID:24387347] [10.1021/np400772h]

16. Qiao JX, Wang TC, Ruel R, Thibeault C, L'Heureux A, Schumacher WA, Spronk SA, Hiebert S, Bouthillier G, Lloyd J, Pi Z, Schnur DM, Abell LM, Hua J, Price LA, Liu E, Wu Q, Steinbacher TE, Bostwick JS, Chang M, Zheng J, Gao Q, Ma B, McDonnell PA, Huang CS, Rehfuss R, Wexler RR, Lam PY..  (2013)  Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.,  56  (22): [PMID:24164581] [10.1021/jm4013906]

17. Farha MA, Koteva K, Gale RT, Sewell EW, Wright GD, Brown ED..  (2014)  Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.,  24  (3): [PMID:24393581] [10.1016/j.bmcl.2013.12.069]

18. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R..  (2004)  [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].,  28  (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2]

19. Anil Kumar KS, Misra A, Siddiqi TI, Srivastava S, Jain M, Bhatta RS, Barthwal M, Dikshit M, Dikshit DK..  (2014)  Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation.,  81  [PMID:24859764] [10.1016/j.ejmech.2014.05.017]

20. Jeon YT, Yang W, Qiao JX, Li L, Ruel R, Thibeault C, Hiebert S, Wang TC, Wang Y, Liu Y, Clark CG, Wong HS, Zhu J, Wu DR, Sun D, Chen BC, Mathur A, Chacko SA, Malley M, Chen XQ, Shen H, Huang CS, Schumacher WA, Bostwick JS, Stewart AB, Price LA, Hua J, Li D, Levesque PC, Seiffert DA, Rehfuss R, Wexler RR, Lam PY..  (2014)  Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.,  24  (5): [PMID:24513044] [10.1016/j.bmcl.2014.01.066]

21. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

22. Boldron C, Besse A, Bordes MF, Tissandié S, Yvon X, Gau B, Badorc A, Rousseaux T, Barré G, Meneyrol J, Zech G, Nazare M, Fossey V, Pflieger AM, Bonnet-Lignon S, Millet L, Briot C, Dol F, Hérault JP, Savi P, Lassalle G, Delesque N, Herbert JM, Bono F..  (2014)  N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.,  57  (17): [PMID:25075638] [10.1021/jm500588w]

23. Yang W, Wang Y, Lai A, Qiao JX, Wang TC, Hua J, Price LA, Shen H, Chen XQ, Wong P, Crain E, Watson C, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY..  (2014)  Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.,  57  (14): [PMID:24931384] [10.1021/jm5006226]

24. Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O..  (2011)  Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,  39  (7): [PMID:21467212] [10.1124/dmd.111.039180]

25. Xu C, Ogburn ET, Guo Y, Desta Z..  (2012)  Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.,  40  (4): [PMID:22232427] [10.1124/dmd.111.042416]

26. Chen H, Li G, Zhan P, Li H, Wang S, Liu X.  (2014)  Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents,  5  (6): [10.1039/C4MD00022F]

27. Misra A, Anil Kumar KS, Jain M, Bajaj K, Shandilya S, Srivastava S, Shukla P, Barthwal MK, Dikshit M, Dikshit DK..  (2016)  Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.,  110  [PMID:26807542] [10.1016/j.ejmech.2016.01.019]

28. WHO Anatomical Therapeutic Chemical Classification, 

29. British National Formulary (72nd edition), 

30. Liao YR, Kuo PC, Tsai WJ, Huang GJ, Lee KH, Wu TS..  (2017)  Bioactive chemical constituents from the root bark of Morus australis.,  27  (2): [PMID:27908762] [10.1016/j.bmcl.2016.11.046]

31. Bhunia SS, Misra A, Khan IA, Gaur S, Jain M, Singh S, Saxena A, Hohlfield T, Dikshit M, Saxena AK..  (2017)  Novel Glycoprotein VI Antagonists as Antithrombotics: Synthesis, Biological Evaluation, and Molecular Modeling Studies on 2,3-Disubstituted Tetrahydropyrido(3,4-b)indoles.,  60  (1): [PMID:27996269] [10.1021/acs.jmedchem.6b01360]

32. DrugMatrix,  [10.6019/CHEMBL3885881]

33. Lesniewska-Kowiel MA, Muszalska I..  (2017)  Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.,  129  [PMID:28219047] [10.1016/j.ejmech.2017.02.011]

34. Ma Y, Fu Y, Khojasteh SC, Dalvie D, Zhang D..  (2017)  Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).,  60  (21): [PMID:28653847] [10.1021/acs.jmedchem.7b00510]

35. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

36. Binsaleh NK, Wigley CA, Whitehead KA, van Rensburg M, Reynisson J, Pilkington LI, Barker D, Jones S, Dempsey-Hibbert NC..  (2018)  Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin.,  143  [PMID:29129512] [10.1016/j.ejmech.2017.11.014]

37. Melo TRF, Kumkhaek C, Fernandes GFDS, Lopes Pires ME, Chelucci RC, Barbieri KP, Coelho F, Capote TSO, Lanaro C, Carlos IZ, Marcondes S, Chegaev K, Guglielmo S, Fruttero R, Chung MC, Costa FF, Rodgers GP, Dos Santos JL..  (2018)  Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.,  154  [PMID:29852459] [10.1016/j.ejmech.2018.05.008]

38. Unpublished dataset, 

39. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

40. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

41. Chen P, Zhang D, Li M, Wu Q, Lam YPY, Guo Y, Chen C, Bai N, Malhotra S, Li W, O'Connor PB, Fu H..  (2019)  Discovery of novel, potent, isosteviol-based antithrombotic agents.,  183  [PMID:31563807] [10.1016/j.ejmech.2019.111722]

42. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

43. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

44. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH (USA) - Clinical Collection,  [10.6019/CHEMBL4513141]

45. Hagihara K, Kazui M, Kurihara A, Ikeda T, Izumi T..  (2012)  Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate.,  40  (9): [PMID:22733806] [10.1124/dmd.112.045914]

46. Kalgutkar AS..  (2020)  Designing around Structural Alerts in Drug Discovery.,  63  (12): [PMID:31497963] [10.1021/acs.jmedchem.9b00917]

47. Liu S,Li S,Yuan D,Wang E,Xie R,Zhang W,Kong Y,Zhu X.  (2021)  Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.,  209  [PMID:33049608] [10.1016/j.ejmech.2020.112893]

48. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

49. Ma BB, Montgomery AP, Chen B, Kassiou M, Danon JJ..  (2022)  Strategies for targeting the P2Y₁₂ receptor in the central nervous system.,  71  [PMID:35640763] [10.1016/j.bmcl.2022.128837]

50. Al-Najjar BO, Saqallah FG, Abbas MA, Al-Hijazeen SZ, Sibai OA..  (2022)  P2Y₁₂ antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies.,  227  [PMID:34731765] [10.1016/j.ejmech.2021.113924]

51. Priestley ES, Banville J, Deon D, Dubé L, Gagnon M, Guy J, Lapointe P, Lavallée JF, Martel A, Plamondon S, Rémillard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A..  (2022)  Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.,  65  (13.0): [PMID:35729784] [10.1021/acs.jmedchem.2c00359]

52. Liu L, Li L, Yuan J, Liu W, Li Y, Zhang S, Huang C..  (2022)  Several non-salt and solid thienopyridine derivatives as oral P2Y₁₂ receptor inhibitors with good stability.,  75  [PMID:36058469] [10.1016/j.bmcl.2022.128969]

53. Kong D, Xue T, Guo B, Cheng J, Liu S, Wei J, Lu Z, Liu H, Gong G, Lan T, Hu W, Hu W, Yang Y..  (2019)  Optimization of P2Y₁₂ Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.,  62  (6.0): [PMID:30843696] [10.1021/acs.jmedchem.8b01971]

54. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(10):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• DrugMatrix
• AstraZeneca Deposited Data
• CO-ADD antimicrobial screening data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• Fraunhofer HDAC6